Blood natural killer cells during treatment in recurrent ovarian cancer
Recent research indicated favorable prognostic impact of intratumoral natural killer (NK) cells in ovarian carcinoma (OC). The role of NK cells during chemotherapy in OC is unknown. We investigated impact of NK cells in OC patients treated with palliative chemotherapy. Participants receiving palliative chemotherapy for recurrent OC ( Median OS in patients with low vs. high NK cell count at baseline was 7.1 months vs. 15.6 months ( A low blood NK cell count in recurrent metastatic ovarian cancer during chemotherapy is associated with unfavorable prognostic impact. Early increase in survival difference based on NK cell status suggests an association between NK cell count and treatment benefit.